GKOS vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GKOS presents a dichotomy between strong operational growth and extreme valuation. The Piotroski F-Score of 5/9 indicates a stable financial foundation, supported by an exceptional current ratio of 4.69 and very low debt/equity (0.16). However, the company remains unprofitable with a negative profit margin of -36.99% and a staggering forward P/E of 282.75. While revenue growth is robust at 35.7%, the bearish insider sentiment and weak technical trend suggest a disconnect between analyst optimism and internal confidence.
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Compare Another Pair
Related Comparisons
GKOS vs JNJ: Head-to-Head Comparison
This page compares Glaukos Corporation (GKOS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.